Evidence map›Paper›PMID 30195772›Full record

ArticleMolecular therapy. Nucleic acids2018

ISO, via Upregulating MiR-137 Transcription, Inhibits GSK3β-HSP70-MMP-2 Axis, Resulting in Attenuating Urothelial Cancer Invasion.

Xirui Guo, Haishan Huang, Honglei Jin, Jiheng Xu, Sanjiv Risal, Jingxia Li, Xin Li, Huiying Yan, Xingruo Zeng, Lei Xue and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. DNMT3A/Cancers · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Xirui GuoNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Haishan HuangSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Honglei JinNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Jiheng XuNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA; School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Sanjiv RisalThe Center of Drug Discovery, Northeastern University, Boston, MA 02115, USA.
Jingxia LiNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA.
Xin LiSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Huiying YanSchool of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
Xingruo ZengNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA.
Lei XueNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA.
Changyan ChenThe Center of Drug Discovery, Northeastern University, Boston, MA 02115, USA.
Chuanshu HuangNelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, USA. Electronic address: chuanshu.huang@nyumc.org.
New York University · USWenzhou Medical University · CNNortheastern University · US

Funding

RESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1M
Reagent/Service CoreP01CA165980 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, XUE-RU · 2013 to 2023
$13.5M
SESN2 and therapeutic effect of Isohapontigenin (ISO)R01CA217923 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COSTA, MAX, SUN, HONG · 2018 to 2022
$2.1M
Mechanisms underlying therapeutic effect of a new compound Isorhapontigenin (ISO)R01CA177665 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2013 to 2018
$1.7M
NCI NIH HHS P01 CA165980NCI NIH HHS R01 CA177665NCI NIH HHS R01 CA217923NIEHS NIH HHS P30 ES000260
6 · The paper itself

Abstract

Our most recent studies demonstrate that miR-137 is downregulated in human bladder cancer (BC) tissues, while treatment of human BC cells with isorhapontigenin (ISO) elevates miR-137 abundance. Since ISO showed a strong inhibition of invasive BC formation in the N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)-induced invasive BC mouse model, the elucidation of a potential biological effect of miR-137 on antagonizing BC invasion and molecular mechanisms underlying ISO upregulation of miR-137 are very important. Here we discovered that ectopic expression of miR-137 led to specific inhibition of BC invasion in human high-grade BC T24T and UMUC3 cells, while miR-137 deletion promoted the invasion of both cells, indicating the inhibitory effect of miR-137 on human BC invasion. Mechanistic studies revealed that ISO treatment induced miR-137 transcription by promoting c-Jun phosphorylation and, in turn, abolishing matrix metalloproteinase-2 (MMP-2) abundance and invasion in BC cells. Moreover, miR-137 was able to directly bind to the 3' UTR of Glycogen synthase kinase-3β (GSK3β) mRNA and inhibit GSK3β protein translation, consequently leading to a reduction of heat shock protein-70 (HSP70) translation via targeting the mTOR/S6 axis. Collectively, our studies discover an unknown function of miR-137, directly targeting the 3' UTR of GSK3β mRNA and, thereby, inhibiting GSK3β protein translation, mTOR/S6 activation, and HSP70 protein translation and, consequently, attenuating HSP70-mediated MMP-2 expression and invasion in human BC cells. These novel discoveries provide a deep insight into understanding the biomedical significance of miR-137 downregulation in invasive human BCs and the anti-cancer effect of ISO treatment on mouse invasive BC formation.

Indexed as

bladder cancerGSK3βHSP70ISOmiR-137MMP-2

Identifiers

PMID30195772
PMCPMC6037888
OpenAlexW2809830668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.